Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Burns DK, et al. Among authors: evans rm. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
Global issues in drug development for Alzheimer's disease.
Doody RS, Cole PE, Miller DS, Siemers E, Black R, Feldman H, Schindler R, Graham S, Heath T, Khachaturian AS, Evans R, Carrillo MC. Doody RS, et al. Alzheimers Dement. 2011 Mar;7(2):197-207. doi: 10.1016/j.jalz.2011.01.001. Alzheimers Dement. 2011. PMID: 21414556
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease.
Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F, Müller U, Kurz A, Zimmer R, Evans RM, Hake A, Gasser T, Oertel WH, Griffin WS, Paul SM, Farlow MR. Du Y, et al. Among authors: evans rm. Neurology. 2000 Aug 22;55(4):480-3. doi: 10.1212/wnl.55.4.480. Neurology. 2000. PMID: 10953177
Advancing combination therapy for Alzheimer's disease.
Salloway SP, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, Paez A, Evans R, Weber CJ, Hendrix JA, Worley S, Bain LJ, Carrillo MC. Salloway SP, et al. Alzheimers Dement (N Y). 2020 Oct 7;6(1):e12073. doi: 10.1002/trc2.12073. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 33043108 Free PMC article.
APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.
Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, Smith-Gamble V, Lane KA, Gao S, Hall KS, Hendrie HC, Murrell JR. Gureje O, et al. Among authors: evans rm. Ann Neurol. 2006 Jan;59(1):182-5. doi: 10.1002/ana.20694. Ann Neurol. 2006. PMID: 16278853 Free PMC article.
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming.
Yang Y, Zhang X, Cai D, Zheng X, Zhao X, Zou JX, Zhang J, Borowsky AD, Dall'Era MA, Corey E, Mitsiades N, Kung HJ, Chen X, Li JJ, Downes M, Evans RM, Chen HW. Yang Y, et al. Among authors: evans rm. Proc Natl Acad Sci U S A. 2024 Oct 15;121(42):e2411321121. doi: 10.1073/pnas.2411321121. Epub 2024 Oct 9. Proc Natl Acad Sci U S A. 2024. PMID: 39383000 Free PMC article.
819 results